Overview

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

Status:
Terminated

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety and preliminary efficacy of escalating doses of VAY736 in relapsed or refractory CLL patients.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals